Usefulness of assessing masked and white-coat hypertension by ambulatory blood pressure monitoring for determining prevalent risk of chronic kidney disease: The Ohasama study

Hypertension Research

Volumn 33, Issue 11, 2010, Pages 1192-1198

  Kanno, Atsuhiro ^a,b   Metoki, Hirohito ^a   Kikuya, Masahiro ^a   Terawaki, Hiroyuki ^c   Hara, Azusa ^a   Hashimoto, Takanao ^a   Asayama, Kei ^c   Inoue, Ryusuke ^a   Shishido, Yoh ^b   Nakayama, Masaaki ^c   Totsune, Kazuhito ^a   Ohkubo, Takayoshi ^c   Imai, Yutaka ^a,c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Midorinosato Clinic   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

ambulatory blood pressure; chronic kidney disease; masked hypertension; white coat hypertension

Indexed keywords

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; JAPANESE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MASKED HYPERTENSION; PREVALENCE; PROTEINURIA; URINALYSIS; WHITE COAT HYPERTENSION;

AGED; BLOOD PRESSURE MONITORING, AMBULATORY; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; JAPAN; KIDNEY DISEASES; MALE; MIDDLE AGED; PREVALENCE; PROTEINURIA; RISK;

EID: 78149300902     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.139     Document Type: Article

References (35)

1. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111: 697-716. (Pubitemid 40216499)
2. Pickering T. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens 1996; 9: 1-11. (Pubitemid 26060844)
3. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21: 821-848.
4. Madin K, Iqbal P. Twenty four hour ambulatory blood pressure monitoring: a new tool for determining cardiovascular prognosis. Postgrad Med J 2006; 82: 548-551.
5. Smith DH, Dubiel R, Jones M. Use of 24-h ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41-50.
6. Stenehjem AE, Os I. Reproducibility of blood pressure variability, white-coat effect and dipping pattern in untreated, uncomplicated and newly diagnosed essential hypertension. Blood Press 2004; 13: 214-224.
7. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognosis of 'masked' hypertension and 'white-coat' hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up form the Ohasama study. J Am Coll Cardiol 2005; 46: 508-515.
8. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustaind mild hypertension: a 10-year follow-up study. Circulation 1998; 98: 1892-1897.
9. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T, Kario K. Short-and long-term incidence of stroke in white-coat hypertension. Hypertension 2005; 45: 203-208.
10. Ugajin T, Hozawa A, Ohkubo T, Asayama K, Kikuya M, Obara T, Metoki H, Hoshi H, Hashimoto J, Totsune K, Satoh H, Tsuji I, Imai Y. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. Arch Intern Med 2005; 165: 1541-1546.
11. Japanese Society of Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec 31, 2007. 2008. http://docs.jsdt.or.jp/overview/.
12. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, Ura N, Kiyohara Y, Hirakata H, Moriyama T, Ando Y, Nitta K, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease (CKD) in Japanese population predicted by MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007; 11: 156-163. (Pubitemid 47012510)
13. Terawaki H, Metoki H, Nakayama M, Ohkubo T, Kikuya M, Asayama K, Inoue R, Hoshi H, Ito S, Imai Y. Masked hypertension determined by self-measured blood pressure at home and chronic kidney disease in the Japanese general population: the Ohasama study. Hypertens Res 2008; 31: 2129-2135.
14. Agarwal R, Andersen MJ. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. Am J Nephrol 2006; 26: 503-510. (Pubitemid 44971743)
15. Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006; 69: 1175-1180.
16. Imai Y, Nagai K, Sakuma M, Sakuma H, Nakatsuka H, Satoh H, Minami N, Munakata M, Hashimoto J, Yamagishi T, Watanabe N, Yabe T, Nishiyama A, Abe K. Ambulatory blood pressure of adults in Ohasama, Japan. Hypertension 1993; 22: 900-912.
17. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P, European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21: 821-848.
18. Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Sekino H, Nihei M, Yoshinaga K. Determination of clinical accuracy and nocturnal blood pressure pattern by new portable devices for monitoring indirect ambulatory blood pressure. Am J Hypertens 1990; 3: 293-301.
19. Association for the Advancement of Medical Instrumentation. American National Standard for Electronic or Automated Sphygmomanometers. Association for the Advancement of Medical Instrumentation: Washington, DC, 1987.
20. Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Sakuma H, Hashimoto J, Sekino H, Imai K, Yoshinaga K. Clinical evaluation of semiautomatic and automatic devices for home blood pressure measurement: comparison between cuff-oscillometric and microphone methods. J Hypertens 1989; 7: 983-990.
21. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
23. Kikuya M, Hansen TW, Thijs L, Björklund-Bodega°rd K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA, IDACO investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 2007; 115: 2145-2152.
24. Asayama K, Ohkubo T, Yoshida S, Suzuki K, Metoki H, Harada A, Murakami Y, Ohashi Y, Ueshima H, Imai Y, Japan Arteriosclerosis Longitudinal Study (JALS) group. Stroke risk and antihypertensive drug treatment in the general population: the Japan arteriosclerosis longitudinal study. J Hypertens 2009; 27: 357-364.
25. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
26. Kostandonis D, Papadopoulos V, Toumanidis S, Papamichael C, Kanakakis I, Zakopou-los N. Topography and severity of coronary artery disease in white-coat hypertension. Eur J Intern Med 2008; 19: 280-284.
27. Minutolo R, Borrelli S, Scigliano R, Bellizzi V, Chiodini P, Cianciaruso B, Nappi F, Zamboli P, Conte G, De Nicola L. Prevalence and clinical correlates of white coat hypertension in chronic kidney disease. Nephrol Dial Transplant 2007; 22: 2217-2223.
28. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 2004; 17: 217-222.
29. Neumann J, Ligtenberg G, Klein IH, Boer P, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49: 506-510.
30. Mena-Martín FJ, Martín-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzúa-Mour-onte D, Castrodeza Sanz JJ, Hortega Study Investigators. Influence of sympathetic activity on blood pressure and vascular damage evaluated by means of urinary albumin excretion. J Clin Hypertens 2006; 8: 619-624.
31. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrecto-mized rats. J Am Soc Nephrol 2000; 11: 1469-1478.
32. Strojek K, Grzeszczak W, Górska J, Leschinger MI, Ritz E. Lowering of microalbumi-nuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of azelnidipine with angiotensin receptor blockers in patients with diabetic nephropathy. J Am Soc Nephrol 2001; 12: 602-605.
33. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE, Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
34. Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
35. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT, PREVEND Study Group. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant 2008; 23: 3851-3858.